Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison

  title={Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison},
  author={Ehsan Motaghi and Masoumeh Ghasemi-Pirbaluti and Mohsen Zabihi},
  journal={Pharmacological Research},

Figures and Tables from this paper

Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses
Biologics and tofacitinib are efficacious and safe for treating UC and can support clinical decision-making.
Recent advances in inflammatory bowel disease therapy.
  • A. Binienda, J. Fichna, M. Sałaga
  • Biology, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2020
A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis
The results indicate that CoQ10 supplementation, along with drug therapy, appears to be an efficient reducer of inflammation in patients with mild-to-moderate UC at a remission phase.
The Role of Resveratrol in the Inflammatory Bowel Diseases
Resveratrol is effective in the treatment of IBD by reducing the production of free radicals and increasing antioxidant enzymes and this polyphenol is capable of reducing the expression of inflammatory markers characteristic of UC and CD.
Treatments of inflammatory bowel disease toward personalized medicine.
Currently available therapeutic options for IBD, biologics under investigation, and recent studies exploring various predictive factors related to PNR and SLR are introduced.
Infliximab in therapy of inflammatory bowels diseases
Dorota Bartusik-Aebisher acknowledges support from the National Center of Science NCN (New drug delivery systems-MRI study, Grant OPUS-13 number 2017/25/B/ST4/02481).


An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
Infliximab proved to be more effective than adalimumab but of similar efficacy to that of golimumab in the induction phase and in clinical remission, while no significant differences in efficacy in the maintenance phase between infliximab and Golimumab or adal optimumab were revealed.
Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs
Infliximab was statistically superior to adalimumab after induction for all outcomes and treatment ranking suggested infliximab as the superior treatment for induction, according to a network meta-analysis of NMA results.
Etrolizumab for ulcerative colitis: the new kid on the block?
Etrolizumab is a humanized monoclonal antibody that selectively blocks lymphocyte trafficking and retention in the gut that appears to be a promising molecule that can benefit UC patients.
Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis
Vedolizumab demonstrated possible clinical benefits in the maintenance setting versus all comparators, irrespective of prior anti-TNF exposure and after adjusting for differences in study design, expanding the understanding of comparative efficacies of biologic treatments for UC.
Infliximab for induction and maintenance therapy for ulcerative colitis.
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis
Chinese patients with moderate to severe active ulcerative colitis treated with low-dose (3.5 mg/kg) or standard-drugs infliximab at weeks 0, 2, and 6 and every 8 weeks thereafter were more likely to have a clinical response at weeks 8 and 30 than those who received placebo.
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
The results suggest that the first TL at week 2, in combination with clinical evaluation, is useful for predicting both short- and long-term outcomes, allowing an earlier decision between continuing IFX or switching to other options.
The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients
Infliximab therapy substantially improved HRQL in patients with ulcerative colitis and was sustained through 1 yr with maintenance infliximab Therapy.